SCHEMBL2118599

SCHEMBL2118599

Cc1ccc(S(=O)(=O)Nc2cc(C)cc(-c3sc(C)nc3C)c2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.55
HTT P42858 3/20 0.55
SMN1; SMN2 Q16637 3/20 0.55
MAPT P10636 4/20 0.49
TP53 P04637 1/20 0.49
ALDH1A1 P00352 7/20 0.48
KDM4E B2RXH2 5/20 0.48
HPGD P15428 2/20 0.48
GLA P06280 1/20 0.48
GAA P10253 1/20 0.48
RORC P51449 1/20 0.48
USP2 O75604 1/20 0.47
HSD17B10 Q99714 1/20 0.47
HSPD1 P10809 1/20 0.46
PTPN2 P17706 1/20 0.46
PTPN1 P18031 1/20 0.46
PTPN5 P54829 1/20 0.46
HSPE1 P61604 1/20 0.46
FFAR4 Q5NUL3 1/20 0.46
CA12 O43570 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2118232 0.89 FFAR4 (0.51) LMNAMAPTTP53ALDH1A1KDM4E
SCHEMBL2119599 0.77 DRD2 (0.53) LMNAHTTSMN1; SMN2MAPTTP53
SCHEMBL18870862 0.77 FFAR4 (0.67) LMNAHTTSMN1; SMN2MAPTTP53
SCHEMBL8091100 0.73 JAK2 (0.46) LMNAHTTGAA
SCHEMBL24996513 0.73 MEN1 (0.76) SMN1; SMN2MAPTALDH1A1KDM4EHPGD
SCHEMBL2119772 0.73 DRD2 (0.56) MAPTTP53ALDH1A1FFAR4
SCHEMBL2118379 0.72 IDH2 (0.50) LMNAHTTMAPTTP53ALDH1A1
SCHEMBL2120312 0.71 HTT (0.59) LMNAHTTSMN1; SMN2MAPTTP53
SCHEMBL2121812 0.71 HTT (0.49) LMNAHTTSMN1; SMN2MAPTTP53
SCHEMBL2118766 0.71 MAPT (0.45) LMNAHTTSMN1; SMN2MAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120095024-A1 TOLUIDINE SULFONAMIDES AND THEIR USE ELARA PHARMACEUTICALS GMBH (DE) 2012-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095024-A1 TOLUIDINE SULFONAMIDES AND THEIR USE HIF1AN, HIF1A, EGLN2 LMNA 2529/4885HTT 1469/4885SMN1; SMN2 3684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.